The Verily subsidiary has the luxury of patient backers. But hungrier rivals could steal a march.
The company is now in the clinic, claiming to have cleared one of the biggest hurdles blocking development of an NK cell therapy.
Two arm’s-length acquisitions and two licensing deals have given Bayer a cell and gene therapy unit; now to bring it all together.
The smaller company believes that its complement C3 inhibitor could make Soliris and Ultomiris redundant in PNH.
The nascent company hopes to prove that its inhaled pan-Jak is best in class.
Pinpointing new forms of the coronavirus could be vital, particularly if it mutates in response to vaccination, the company says.
Pivotal trials of Astrazeneca's Covid-19 antibody get under way, with hopes that a longer half-life and more convenient dosing will set the project apart.
As antibody tests pile up, Oxford Immunotec is working on an assay to detect T cell responses to the coronavirus.
Analysts see semaglutide helping Novo Nordisk to beat its sales target in obesity, but the company has bigger ambitions for earlier projects.